Bli medlem
Bli medlem

Du är här

2016-08-29

Karolinska Development – Q2 2016 Interim Report - invitation to conference call and webcast

Karolinska Development – Q2 2016 Interim Report - invitation to conference call
and webcast

STOCKHOLM - 29 August 2016. Karolinska Development AB (Nasdaq Stockholm: KDEV)
will publish its Q2 2016 Interim Report on 31 August 2016. The company will
also host a conference call and an online presentation on the same day at 2 pm
CEST

Please dial in at one of the following numbers a few minutes before the start
of the conference call:

-- From Sweden: +46 (0) 8 505 564 74
-- From the US: +1 855 753 22 30
-- From the UK: +44 (0) 20 336 453 74

The presentation will also be webcast and can be accessed from the following
web address:
http://edge.media-server.com/m/p/84ypx7fr

Host: Jim Van heusden, CEO.

For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden@karolinskadevelopment.com

Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange@karolinskadevelopment.com

David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk

TO THE EDITORS

About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying
medical innovation and investing in the creation and growth of companies
developing these assets into differentiated products that will make a
difference to patients’ lives and provide an attractive return on investment.

Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who
are leaders in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to provide the
greatest chance of success.

Karolinska Development has established a portfolio of 12 companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.

The Company is led by a team including investment professionals with strong
venture capital backgrounds, experienced company builders and entrepreneurs,
with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.